Survival in patients treated with first- and second-generation EGFR-TKIs, osimertinib (third-generation EGFR-TKI), and combined EGFR-TKI plus VEGF inhibitor/cytotoxic therapy was analyzed by multiple regression analysis with adjustments for sex, performance status, EGFR mutation status, PD-L1 expression level, and the presence or absence of brain metastasis using a Cox proportional hazards model.... In conclusion, combined therapy was associated with a significant reduction in the risk of progression compared with first- and second-generation EGFR-TKI monotherapy, and therefore, may be promising for the treatment of patients of NSCLC.

We retrospectively reviewed the medical records of 61 patients treated with osimertinib as primary therapy for EGFR mutation-positive advanced NSCLC….The EGFR mutation was exon19 deletion in 52.5% and exon21 L858R in 44.3% of patients….Median PFS was 19.5 months (95% confidence interval [CI]: 10.6–31.6)....The objective response rate was 68.9%, and disease control rate was 93.4%....For PD-L1 TPS, we divided the data into three categories. The median PFS was 20.4 months (95% CI: 8.4–31.6) for TPS <1%, 18.0 months (95% CI: 7.2-NE) for TPS from 1–49%, and 12.4 months (5.0-NE) for TPS ≥50% (Figure 3d). For TPS ≥1%, the duration to PFS was 18.0 months (9.6-NE) (Figure 3e), and for <50%, it was 19.7 months (95% CI: 10.6–NE) (Figure 3f)...our study demonstrated in real-world settings that patients with EGFRm+ advanced NSCLC could have good PFS when osimertinib is used as first-line therapy.